Poll Claire's Form 4 filing
Verona Pharma plc (VRNA) · filed Dec 27, 2022
- Accession no.
- 0001104659-22-130251
- Filed
- Dec 27, 2022
- Trade date
- Nov 21, 2021-Dec 22, 2022
- Filing delay
- 401 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 11 non-derivative transactions. Open-market sales total $645.6K. It was filed 401 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Poll ClaireCIK 0001836820 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2021 | Ordinary Shares | GGiftDisposed | −90,104 | $0.00 | $0 | 2,472,951 | Direct | |
| Nov 21, 2021 | Ordinary Shares | GGiftAcquired | +90,104 | $0.00 | $0 | 573,944 | Indirect | |
| Feb 22, 2022 | Ordinary Shares | GGiftDisposed | −90,104 | $0.00 | $0 | 2,382,847 | Direct | |
| Feb 22, 2022 | Ordinary Shares | GGiftAcquired | +90,104 | $0.00 | $0 | 664,048 | Indirect | |
| May 22, 2022 | Ordinary Shares | GGiftDisposed | −90,104 | $0.00 | $0 | 2,292,743 | Direct | |
| May 22, 2022 | Ordinary Shares | GGiftAcquired | +90,104 | $0.00 | $0 | 754,152 | Indirect | |
| Aug 21, 2022 | Ordinary Shares | GGiftDisposed | −90,104 | $0.00 | $0 | 2,202,639 | Direct | |
| Aug 21, 2022 | Ordinary Shares | GGiftAcquired | +90,104 | $0.00 | $0 | 844,256 | Indirect | |
| Nov 22, 2022 | Ordinary Shares | GGiftDisposed | −170,000 | $0.00 | $0 | 2,032,639 | Direct | |
| Nov 22, 2022 | Ordinary Shares | GGiftAcquired | +170,000 | $0.00 | $0 | 1,014,256 | Indirect | |
| Dec 22, 2022 | Ordinary Shares | SSaleDisposed | −240,000 | $2.69F4 | −$645,600 | 774,256 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The price reported represents the weighted average sale price of the ADSs divided by eight (8). These shares were sold in multiple transactions at prices ranging from $2.675 to $2.7138, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.